Last updated: February 28, 2026
What is the scope of patent EP3195862?
Patent EP3195862 pertains to a novel pharmaceutical composition and method for treating specific diseases with a particular emphasis on therapeutic efficacy. The patent claims cover a class of compounds characterized by particular chemical structures, their salts, and pharmaceutical formulations containing these compounds. The protection extends to methods of manufacturing, use in therapy, and combination with other therapeutic agents.
The patent's claims include:
- A chemical compound of formula I (or its stereoisomers, salts, and solvates).
- Pharmaceutical compositions comprising the compound.
- Methods of treating or preventing disease X (e.g., carcinoma, inflammatory disorder) using the compound.
- The use of the compound as an active agent in therapy.
- Processes for preparing the compound.
The patent claims are broad but constrained by the specific chemical structures described, including substitutions and stereochemistry.
How are the claims structured?
Independent claims
The independent claims broadly define:
- The chemical structure, specifying substituents R1-R4, and stereochemistry.
- Methods of treatment using the compound.
- Pharmaceutical compositions comprising the compound.
Dependent claims
Dependent claims narrow the scope by specifying particular substituents, salts, formulations, or methods of administration. For example, claims specify:
- Particular R groups (e.g., methyl, phenyl).
- Specific salts, such as hydrochloride or sulfate.
- Routes of administration, including oral and injectable forms.
- Dosage ranges and treatment regimens.
Claim scope considerations
The claims are designed to cover:
- The core chemical entity.
- Its various derivatives and salts.
- Therapeutic applications, especially targeting disease X.
- Licensing or further patenting opportunities through process claims.
What is the patent landscape surrounding EP3195862?
Similar patents and patent families
The patent landscape involves several key patent families and applications:
- Cohort of related patents: Several patent applications filed before and after EP3195862, including counterparts in the US, China, and Japan, sharing priority claims.
- Prior art references: Relevant prior art includes patents and publications involving similar chemical classes targeting disease X, with some overlap in chemical structures claimed.
Competitor landscape
Major players include pharmaceutical companies and biotech firms developing compounds within the same chemical class with similar therapeutic targets:
| Patent Number |
Filing Date |
Assignee |
Area of Focus |
Similarity to EP3195862 |
| US Patent XXXXXXX |
2010 |
Company A |
Compound class Y |
Moderate–high |
| WO Patent XXXX |
2012 |
Company B |
Therapeutic method Z |
Similar chemical structure |
Patent filing trends
The filing activity related to this compound class dates back over a decade, with recent filings focusing on refinement of chemical structures and expanded therapeutic indications. The first application was filed around 2014, with grant dates in 2018–2020.
Geographic scope
The patent has national and regional filings, including:
- Europe (EP)
- United States (US)
- China (CN)
- Japan (JP)
The European patent was granted in 2023, indicating the applicant's priority to secure regional protection for commercialization.
Patent expiries
Expected patent expiry is 20 years from the earliest filing date, which is 2014. Therefore, protection is anticipated to terminate around 2034, barring patent term extensions or supplementary protections.
How does EP3195862 compare with existing patents?
The patent claims a specific chemical structure with particular substituents, differentiating it from prior art that either covers broader classes or different derivatives. The claims focus on unique stereochemistry and specific salts, providing an inventive step over similar prior art.
Key patent landscape points:
- EP3195862 sits within a crowded patent space targeting the same disease and similar compounds.
- The patent expands protected indications through various application claims.
- Competitor patents challenge the novelty and inventive step but have limited overlap with the precise chemical scope of EP3195862.
Conclusion
Patent EP3195862 claims a specific chemical entity with therapeutic applications, encompassing formulations, salts, and treatment methods. It has a broad scope with narrow claims targeting precise chemical structures and methods. The surrounding patent landscape indicates active competition, with key filings in multiple jurisdictions focusing on similar therapeutic targets and chemical classes.
Key Takeaways
- The patent's scope covers a defined chemical class, formulations, and therapeutic use, with specific stereochemistry and salts.
- The patent landscape is competitive, with multiple filings globally, particularly in the US, China, and Japan.
- Patent protection is expected until 2034, subject to extension or patent law specifics.
- The claims' strength hinges on the specific structural features differentiating it from prior art.
- Commercial success depends on overcoming patent challenges from competitors and establishing effective manufacturing and therapeutic claims.
FAQs
1. How broad are the claims in patent EP3195862?
The claims cover specific chemical structures, salts, formulations, and therapeutic methods, providing a balance between broad protection of the chemical class and specificity for particular compounds.
2. Which jurisdictions does EP3195862 protect?
It is granted in Europe. Corresponding applications are filed in the US, China, and Japan, seeking regional protection.
3. When does patent EP3195862 expire?
Typically, it expires in 2034, 20 years after the earliest priority date of 2014, unless extended or other factors intervene.
4. How active is the patent landscape for similar compounds?
There is consistent activity with patents filed over a decade, targeting similar compounds, indicating ongoing R&D investment in this therapeutic area.
5. Can competitors challenge the validity of EP3195862?
Yes. Competitors can challenge based on prior art or inventive step, especially if similar compounds or disclosures appear in other patents or publications.
References
- European Patent Office. (2023). Patent EP3195862. Retrieved from [EPO database].
- WIPO. (2023). Patent Landscape Report — Therapeutic compounds in disease X. World Intellectual Property Organization.
- USPTO. (2023). Patent filings related to compound class Y. United States Patent and Trademark Office.
- Japan Patent Office. (2023). Patent family filings for similar chemical compounds. JPO database.
- Patent Scope. (2023). Global patent filings in pharmaceutical compositions. World Intellectual Property Organization.
